Drug intelligence / Profile preview

LY3461767

Development stage: Phase 1
Lead developer: Eli Lilly
Modality: Blood Coagulation Factors → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules
Administration: Subcutaneous, Intravenous

Overview

LY3461767 is an investigational drug developed by Eli Lilly for the treatment of chronic heart failure with reduced ejection fraction (HFrEF). It acts as an agonist of neuregulin 4 (NRG4), a member of the neuregulin family involved in cellular signaling pathways that may influence cardiac function. The drug is administered via subcutaneous or intravenous infusion and has been evaluated in Phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy participants and patients with heart failure. As of mid-2024, it has not received regulatory approval for any indication[1][3][4][5].

Targets

ERBB4 (Erb-b2 receptor tyrosine kinase 4)

Beyond the preview

Go deeper on LY3461767.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY3461767.

Explore the full profile